Prostate Tumor Antigen Discovery: Development of a Novel Genetic Approach
Abstract
The overall objective of this study was to determine the in vitro immunogenicity of products of prostate tumors that could potentially be used as tumor vaccines. To achieve this goal, the following specific tasks were undertaken: (1) detection of recall T cell responses to known tumor antigens, (2) optimization of antigen delivery to and presentation by dendritic cells (DC), and (3) develop oligonucleotide-derived tumor antigens in cDNA libraries. T cell recall responses to prostate specific antigens (PSA) were found in patients with autoimmune prostatitis and prostate cancer showing that this protein is potentially immunogenic. CD4+ and CD8+ T cell lines established from these patients were used to identify previously un-described HLA Class I and Class II allele-specific epitopes in PSA. Methods were developed to isolate DC precursors from peripheral blood and to use these cells to generate de novo immune T cell responses in vitro. DCs armed with PSA-generated CD4+ T cell responses, while both CD4+ and CD8+ responses were observed with DCs armed with PSA/anti-PSA immune complexes. Only CD4+ T cell responses developed with DCs transfected with RNA from LNCaP cell lines. These studies established the feasibility of using PSA as a vaccine for prostate cancer immunotherapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2001
- Accession Number
- ADB282266
Entities
People
- Dean L. Mann
Organizations
- University of Maryland, Baltimore